Press releases

Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 35th Annual Strategic Decisions Conference on Wednesday, May 29, 2019 in New York City. Mike Mahoney, chairman and chief...

Boston Scientific (NYSE: BSX) today announced acute results from the UNTOUCHED study evaluating safety and efficacy of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System for...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Vertiflex, Inc., a privately-held company which has developed and commercialized the...

Boston Scientific Corporation (NYSE: BSX) will participate in the 2019 UBS Global Healthcare Conference on Tuesday, May 21, 2019 in New York City. Art Butcher, senior vice president and president,...

Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive...

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San...

Boston Scientific Corporation (NYSE: BSX) will participate in the Bank of America Merrill Lynch Healthcare Conference 2019 on Wednesday, May 15, 2019 in Las Vegas. Dan Brennan, executive vice...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.493 billion during the first quarter of 2019. This represents growth of 4.8 percent on a reported basis, 7.8 percent on an...

Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge™ Aortic Valve System. Delivered via a...

On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse (POP) to stop selling and...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2019 on Wednesday, April 24,...

Boston Scientific Corporation (NYSE: BSX) announced data from the AF-FICIENT I study during a late-breaking clinical trial session today at EHRA 2019, the annual congress of the European Heart...

Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device in

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal, on...

Solutions for nutrition support and early detection of respiratory issues win and place at Connected Patient Challenge competition focused on chronic conditions MARLBOROUGH, Mass., February 28,...

Boston Scientific Corporation (NYSE: BSX) will participate in the Cowen and Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 in Boston. Dan Brennan, executive vice president...

Boston Scientific Corporation (NYSE: BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million of 3.450% notes...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $4.3 billion aggregate principal amount of its senior notes under the Company's shelf registration...

Boston Scientific Corporation (NYSE: BSX) will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 in New York City. Joe Fitzgerald, executive...

On February 12, 2019, the U.S. Food and Drug Administration (FDA) convened an advisory panel of experts to discuss the safety and effectiveness of surgical mesh placed transvaginally to treat...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.561 billion during the fourth quarter of 2018. This represents growth of 6.3 percent on a reported basis, 8.2 percent on an...

Boston Scientific Corporation (NYSE: BSX) today announced that data from a randomized clinical trial demonstrate that Rezūm™ Water Vapor Therapy, a minimally invasive treatment for benign...

Boston Scientific Corporation (NYSE: BSX) has launched the Vercise™ Primary Cell (PC) and Vercise Gevia™ Deep Brain Stimulation (DBS) Systems featuring the Vercise Cartesia™ Directional...

Today, Boston Scientific (NYSE: BSX) announced positive 12-month data demonstrating that patients who were treated with the VICI VENOUS STENT® System for iliac and femoral vein obstructions...

Boston Scientific Corporation (NYSE: BSX) and Edwards Lifesciences Corporation (NYSE: EW) today announced that the companies have reached an agreement to settle all outstanding patent disputes...

Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.56 billion during the fourth quarter of 2018. This represents...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2018 on Wednesday,...

Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Millipede, Inc, a privately-held company in Santa Rosa, Calif., upon its recent...

Boston Scientific Corporation (NYSE: BSX) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 in San Francisco, California. Mike Mahoney, chairman and...

Boston Scientific Corporation (NYSE: BSX) today announced that a jury in the United States (U.S.) District Court for the District of Delaware determined that the Boston Scientific U.S. patent...

Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 in New York City. Susie...

Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York City. Art Butcher, senior vice president and...

Patient safety is Boston Scientific’s highest priority and our constant focus in helping care for people living with complex, debilitating and often life-threatening conditions. We provide...

Boston Scientific Corporation (NYSE: BSX) will participate in the 30th Annual Piper Jaffray Healthcare Conference on Thursday, November 29, 2018 in New York City. Jeff Mirviss, senior vice...

Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a company headquartered in the United Kingdom, which...

Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 in New York City. David Pierce,...

Boston Scientific Corporation (NYSE: BSX) will participate in the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 in New York City. Dan Brennan, executive vice president and chief...

Boston Scientific Corporation (NYSE: BSX) will participate in the 27th Annual Credit Suisse Healthcare Conference on Wednesday, November 14, 2018 in Scottsdale, Arizona. Joe Fitzgerald, executive...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.393 billion during the third quarter ended September 30, 2018. This represents growth of 7.7 percent on a reported basis, 9.1...

Boston Scientific Corporation (NYSE: BSX) today announced the District Court of Dusseldorf, Germany has determined that Edwards Lifesciences Corporation's Sapien 3 Ultra™ device infringed a...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Augmenix, Inc., a privately-held company that developed and commercialized the SpaceOAR® Hydrogel System...

CHICAGO and MARLBOROUGH, Mass., Oct. 10, 2018 -- Boston Scientific Corporation (NYSE: BSX) today announced that its Solyx™ Single Incision Sling (SIS) System achieved treatment success, meeting...

MARLBOROUGH, Mass., Oct. 1, 2018– Boston Scientific Corporation (NYSE: BSX) today announced a worldwide call for submissions to the fourth annual Boston Scientific Connected Patient Challenge,...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2018 on Wednesday, October...

Today, Boston Scientific (NYSE: BSX) announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application to market the Eluvia™ Drug-Eluting Vascular...

Today, Boston Scientific (NYSE: BSX) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery (SFA). Results were...

Boston Scientific Corporation (NYSE: BSX) today announced the global launch of the LithoVue Empower™ Retrieval Deployment Device, designed to be used with the LithoVue™ Single-Use Digital...

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the...

Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 in New York City. Mike Mahoney, chairman...